SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-003837 to Scilex Holding Co (SCLX, SCLXW) (CIK 0001820190) (SCLX)

Scilex Holding Co (SCLX, SCLXW) (CIK 0001820190)
Date: April 17, 2023 · CIK: 0001820190 · Accession: 0000000000-23-003837

AI Filing Summary & Sentiment

File numbers found in text: 333-271204

Date
April 17, 2023
Author
Not clearly detected
Form
UPLOAD
Company
Scilex Holding Co (SCLX, SCLXW) (CIK 0001820190)

Letter

United States securities and exchange commission logo April 17, 2023 Jaisim Shah Chief Executive Officer & President Scilex Holding Company 960 San Antonio Road Palo Alto, CA 94303 Re:Scilex Holding Company Registration Statement on Form S-1 Filed April 10, 2023 File No. 333-271204 Dear Jaisim Shah: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Cindy Polynice at 202-551-8707 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jeff Hartlin, Esq.

Show Raw Text
United States securities and exchange commission logo
April 17, 2023
Jaisim Shah
Chief Executive Officer & President
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Re:Scilex Holding Company
Registration Statement on Form S-1
Filed April 10, 2023
File No. 333-271204
Dear Jaisim Shah:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Cindy Polynice at 202-551-8707 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Jeff Hartlin, Esq.